Stomach Cancer Drugs Market Size, Share, Analysis and Forecast 2019-2026
Market Overview
During the forecast period, the Stomach Cancer Drugs Market is expected to grow at a CAGR of 15%. Despite major advances in treatment, stomach cancer remains one of the leading causes of cancer-related deaths worldwide.Late diagnosis of the disease results in patients missing out on the potential of a surgical cure, and cancer has grown to an advanced stage by the time it is diagnosed, resulting in high fatality rates.
Gastric cancer is a prevalent malignancy, especially in South America, Middle and Eastern Europe, and Eastern Asia, where the economies are still developing. Gastric cancer cases in China make up 44.2 percent of all new gastric cancer cases worldwide.
According to estimates, there were 769,728 stomach cancer event cases in Asia in 2018, with that number anticipated to climb to 947,186 by 2025. Although chemotherapy can help patients with advanced stomach cancer live longer, the overall survival rate remains low. A large number of studies have demonstrated that molecular targeted therapy can increase the survival rates of patients with gastric cancer.
Chemotherapy is the most common method of cancer cell treatment, and it is used to inhibit or delay cancer cell multiplication. Chemotherapy kills, destroys, or damages cancer cells in a specific area, whereas surgery and radiation therapy work across the body. Chemotherapy can thus destroy and injure cancer cells that have moved beyond the initial tumor to other places of the body.
North America currently dominates the market and is expected to continue to do so during the forecast period.
North America is estimated to lead the global market for the duration of the forecast period. The increased prevalence of stomach cancer, as well as the availability of improved technologies in cancer research and treatment institutes, are to blame.
Gastric cancer is a prevalent malignancy, especially in South America, Middle and Eastern Europe, and Eastern Asia, where the economies are still developing. Gastric cancer cases in China make up 44.2 percent of all new gastric cancer cases worldwide.
According to estimates, there were 769,728 stomach cancer event cases in Asia in 2018, with that number anticipated to climb to 947,186 by 2025. Although chemotherapy can help patients with advanced stomach cancer live longer, the overall survival rate remains low. A large number of studies have demonstrated that molecular targeted therapy can increase the survival rates of patients with gastric cancer.
Key Market Trends
In the Stomach Cancer Drugs Market, the chemotherapy segment is expected to hold a significant market share.Chemotherapy is the most common method of cancer cell treatment, and it is used to inhibit or delay cancer cell multiplication. Chemotherapy kills, destroys, or damages cancer cells in a specific area, whereas surgery and radiation therapy work across the body. Chemotherapy can thus destroy and injure cancer cells that have moved beyond the initial tumor to other places of the body.
North America currently dominates the market and is expected to continue to do so during the forecast period.
North America is estimated to lead the global market for the duration of the forecast period. The increased prevalence of stomach cancer, as well as the availability of improved technologies in cancer research and treatment institutes, are to blame.
Comments
Post a Comment